Neoplasms

Symptoms and General Pathology

All Conditions

Nervous System Diseases

Neoplasm Metastasis

Epilepsy

Seizures

Neoplastic Processes

Brain Diseases

Central Nervous System Diseases

Neurologic Manifestations

Pharmaceutical Solutions

All Drugs and Chemicals

Anticonvulsants

Brivaracetam

Subjects in this arm will receive open-label Brivaracetam.

* Pharmaceutical form: Solution for injection
* Concentration: 10 mg/ml
* Route of administration: Intravenous injection

UCB Cares

The purpose of the study is to evaluate the safety and tolerability of intravenous (iv) brivaracetam (BRV) as adjunctive therapy administered as a replacement for oral BRV at doses ranging from BRV 50 mg/day to 200 mg/day in Japanese subjects \>=16 years of age with partial seizures with or without secondary generalization and to evaluate the partial seizure frequency after switching from oral administration to iv BRV.

A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization

A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization

An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.

A SAE must meet 1 or more of the following criteria:

* Death
* Life-threatening
* Significant or persistent disability/incapacity
* Congenital anomaly/birth defect
* Initial inpatient hospitalization or prolongation of hospitalization
* Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or subject and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious

Partial Seizures can be classified into one of the following three groups: Simple Partial Seizures, Complex Partial Seizures, Partial Seizures evolving to Secondarily Generalized Seizures. The partial seizure frequency will be assessed using the seizure count information recorded on the daily record card (DRC). The written information will be discussed with the subject in order to ensure completeness and accuracy. As a result of the discussion, the Investigator will assess the seizures according to the International League Against Epilepsy (ILAE) codes and record the seizure types and frequency on the DRC.

The plasma concentration level of brivaracetam 5 minutes postdose on Day 1.

The plasma concentration level of brivaracetam 5 minutes postdose on Day 2.

The plasma concentration level of brivaracetam 5 minutes postdose on Day 5.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization	NCT03685630	Partial Seizure... Epilepsy	Brivaracetam	16 Years -	UCB Pharma
A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization	NCT03685630	Partial Seizure... Epilepsy	Brivaracetam	16 Years -	UCB Pharma

Spots Global Cancer Trial Database for japanese subjects